Premium
Differential effect of mu, delta, and kappa opioid agonists on adenylate cyclase activity
Author(s) -
de Montis G. M.,
Devoto P.,
Preti A.,
Tagliamonte A.
Publication year - 1987
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.490170416
Subject(s) - dadle , adenylate kinase , cyclase , dynorphin , chemistry , medicine , endocrinology , striatum , guinea pig , dopamine , enkephalin , opioid , biology , biochemistry , receptor , opioid peptide
D‐Ala 2 , D‐Leu 5 ‐enkephalin (DADLE) and dynorphin l–13 (Dyn l–13 ) inhibited striatal adenylate cyclase activity, both basal and dopamine‐stimulated (DA), in rats and guinea pigs. The κ‐agonists bremazocine (BRZ), U‐50,488 (trans‐3,4‐dicloro‐N‐methyl‐N‐[2‐(1‐pyrrolidiny1)‐cyclohexyl]‐benzeneacetamide), and U‐69,593 (5α, 7α 8β)‐(‐)‐N‐methyl‐N‐(7‐(l‐pyrrolidiny1)‐1‐oxaspiro (4.5) dec‐8yl) benzeneacetamide inhibited only the basal adenylate cyclase activity, and such an effect was restricted to guinea pig striatum, an area known to contain a high density of K‐binding sites. Moreover, BRZ was found to antagonize the inhibitory effect of both DADLE and Dyn l–13 in rat striatum.